Literature DB >> 23355794

The importance of local control in high-risk locally advanced prostate cancer.

S Sridharan1, P Warde.   

Abstract

Prostate cancer is a common malignancy worldwide, and in Canada, it is the most frequently diagnosed cancer in men. The stratification of prostate cancer into risk categories has allowed for improved counselling of patients and provides guidance for treatment selection. However, the exact definition of high-risk prostate cancer remains controversial, and that lack of consensus remains a barrier to assessing available data from various institutions and from clinical trials. The proportion of patients with locally advanced high-risk disease has fallen in the last 20 years largely because of screening for prostate-specific antigen, but management in this population continues to be an important clinical problem. A factor that has emerged in recent years is the importance of local disease control, with data from multiple randomized trials suggesting that local therapy improves progression-free survival, disease-free survival, and overall survival. Further research in this population is necessary to improve outcomes.

Entities:  

Keywords:  Prostate cancer; local control; locally advanced; radiotherapy

Year:  2012        PMID: 23355794      PMCID: PMC3553563          DOI: 10.3747/co.19.1279

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  36 in total

1.  Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials.

Authors:  M Roach; J Lu; M V Pilepich; S O Asbell; M Mohiuddin; R Terry; D Grignon; M Mohuidden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

2.  Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.

Authors:  Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 3.  The changing face of prostate cancer.

Authors:  Matthew R Cooperberg; Judd W Moul; Peter R Carroll
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

4.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

5.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

6.  Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer.

Authors:  Lennart Aström; Dorte Pedersen; Claes Mercke; Sten Holmäng; Karl Axel Johansson
Journal:  Radiother Oncol       Date:  2004-11-25       Impact factor: 6.280

Review 7.  Controversies in prostate cancer radiotherapy: consensus development.

Authors:  H Lukka; P Warde; T Pickles; G Morton; M Brundage; L Souhami
Journal:  Can J Urol       Date:  2001-08       Impact factor: 1.344

8.  A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.

Authors:  Derek B Chism; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

9.  Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study.

Authors:  Elnasif Arrayeh; Antonio C Westphalen; John Kurhanewicz; Mack Roach; Adam J Jung; Peter R Carroll; Fergus V Coakley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

10.  Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era.

Authors:  Anthony V D'Amico; Kerri Cote; Marian Loffredo; Andrew A Renshaw; Delray Schultz
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

View more
  2 in total

1.  Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥70 years.

Authors:  Kyo Chul Koo; Dae Chul Jung; Seung Hwan Lee; Young Deuk Choi; Byung Ha Chung; Sung Joon Hong; Koon Ho Rha
Journal:  Prostate Int       Date:  2014-05-21

Review 2.  Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis.

Authors:  Arie Carneiro; Willy Baccaglini; Felipe P A Glina; Paulo P Kayano; Victor M Nunes; Oren Smaletz; Wanderley Marques Bernardo; Icaro Thiago de Carvalho; Gustavo Caserta Lemos
Journal:  Int Braz J Urol       Date:  2017 Jul-Aug       Impact factor: 1.541

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.